SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amidst a fervent debate over Bitcoin's near-term price direction, with discussions highlighting recent ETF outflows and broader market dynamics. The community remains sharply divided, as many anticipate a "parabolic" rally for Bitcoin as a hedge against inflation, while others warn of an impending "crypto winter" and significant price corrections based on historical cycles and perceived lack of intrinsic value.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

iShares Ethereum Trust ETF ($ETHA) is trending amidst strong speculation surrounding spot Ethereum ETF approvals, particularly those offering staking, which is expected to drive institutional demand. The recent "Fusaka Upgrade" is also a key talking point, with its impact on Ethereum's burn rate fueling bullish outlooks and active options trading. While many investors are actively 'buying the dip' and positioning for a potential decoupling from Bitcoin, others maintain caution regarding crypto market volatility.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is generating significant buzz after the FDA accepted its Biologics License Application for Veligrotug, granting Priority Review for Thyroid Eye Disease and setting a PDUFA target. The community is widely discussing Veligrotug's potential as a best-in-class treatment, citing its strong efficacy across both active and chronic TED compared to current therapies, which fuels analyst upgrades and M&A speculation for the company's innovative pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Vanda Pharmaceuticals Stock Wednesday?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.read more...

Vanda Pharmaceuticals Stock Surges 29% After FDA Clears Motion Sickness Drug

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) shares jumped 29.13%, trading at $9.08, up $2.05, after the company announced that the U.S. Food and Drug Administration approved NEREUS (tradipitant...

Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week High - Here's What Happened

Vanda Pharmaceuticals (NASDAQ:VNDA) Reaches New 12-Month High - Still a Buy...

Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 12,270 call options on the stock. This represents an...

Futures Flat On Last Trading Day Of 2025, Silver Slides

Futures Flat On Last Trading Day Of 2025, Silver Slides Stocks are ending a third straight year of double-digit gains in subdued fashion as an expected seasonal rally fails to gain traction. Silver's...

VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains 

Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Recommendation of "Hold" by Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have received a consensus recommendation of "Hold" from the five analysts that are currently covering the company, Marketbeat.com...

Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

<ul class="summary-bullets"><li>Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo.</li><li>Vanda is also advancing Tradipitant in clinical development for gastroparesis and nausea linked to GLP-1 therapies.</li><li>Jefferies raised VNDA stock target price to $7.5 from $5, stating Nereus is a potential $100–$300 million opportunity.</li></ul>Shares of Vanda Pharmaceuticals (VNDA) surged over 18% in pre-market trading on Wednesday after the company received U.S. Food and Drug Administration (FDA) approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting.<a href="https://stocktwits.com/symbol/VNDA">VNDA shares</a> are on track to open at their highest levels in over three years.The FDA approval marks the first new pharmacologic treatment for motion sickness in more than 40 years. Vanda expects to launch NEREUS in the coming months.<h2 class="st-heading-2">Strong Clinical Evidence</h2>The FDA’s decision was supported by data from three clinical studies involving patients with documented histories of motion sickness. Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo. In the Motion Syros study, vomiting rates fell to roughly 18%-20% with NEREUS, compared with more than 44% with placebo.Similar results were seen in the Motion Serifos trial, where risk reductions exceeded 50%–70%. Across all studies, the drug demonstrated a favorable safety profile consistent with short-term use.Motion-induced vomiting is triggered by conflicting signals between the eyes, inner ear, and body sensors, which activate nausea pathways in the brain. NEREUS works by selectively blocking neurokinin-1 (NK-1) receptors, directly targeting a key mechanism responsible for nausea and vomiting.“This approval underscores the strong scientific evidence in the antiemetic effects of NEREUS™ in motion sickness. For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options,” said Mihael H. Polymeropoulos, President, CEO, and Chairman of the Board of Vanda Pharmaceuticals.Beyond motion sickness, Vanda is advancing tradipitant in clinical development for other conditions driven by similar pathways, including gastroparesis and nausea linked to GLP-1 therapies. Last month, Vanda reported that Tradipitant cut vomiting by 50% versus placebo in a trial for nausea and vomiting caused by the GLP-1 drug Wegovy in overweight and obese adults.<h2 class="st-heading-2">Jefferies Raises Price Target</h2>Jefferies raised its price target on Vanda Pharmaceuticals to $7.50 from $5, maintaining a ‘Hold’ rating after the FDA approved Nereus, according to The Fly.The firm sees Nereus as a potential $100 million – $300 million opportunity for preventing motion-induced vomiting and expects it to be priced above over-the-counter alternatives like Dramamine. Jefferies also notes the approval supports the drug’s acute use in other indications, including GLP-1–associated nausea and vomiting.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes. VNDA was also among the top trending stocks on the platform at the time of writing.<figure class="image"><img style="aspect-ratio:913/94;" src="https://news.stocktwits-cdn.com/VNDA_sentiment_jpg_1f867c7f0c.webp" alt="VNDA sentiment.jpg" width="913" height="94"><figcaption>VNDA's Sentiment Meter and Message Volumes at Premarket on Dec. 31, 2025 | Source: Stocktwits</figcaption></figure>One user expects the stock to be a ‘multi-day runner’ due to the approval.<stembedurl>https://stocktwits.com/HoHoHoHum/message/640482824</stembedurl>Year-to-date, the shares have gained around 45%.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/arthur-hayes-continues-ethereum-exit-with-2-million-defi-token-buying-spree/cL7BTXOREy6">Arthur Hayes Continues Ethereum Exit With Fresh $2 Million DeFi Token Buying Spree</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

VNDA Stock On Track To Open At Three-Year High – FDA Clears First New Motion Sickness Drug In Decades

Vanda is expected to launch NEREUS, a motion-sickness treatment aimed at preventing vomiting, in the coming months.

Equity

<ul class="summary-bullets"><li>The subdued tone follows a third straight day of marginal losses for major indices.</li><li>Retail sentiment on major ETFs such as SPY and QQQ remains mixed on Stocktwits.</li><li>December FOMC minutes showing a divided Fed on 2026 rate cuts continue to weigh on sentiment.</li></ul>U.S. stock futures were trading slightly lower early Wednesday,&nbsp;signalling a third consecutive day of marginal losses for the major indices. As markets head into the final session of 2025, caution prevails following the December FOMC minutes, which revealed a divided Federal Reserve regarding the pace of interest rate cuts in 2026.As of 3:10 a.m. ET on Wednesday, Nasdaq 100 futures were down 0.3%, S&amp;P 500 futures fell 0.19%, and the Dow futures fell 0.1%, while Russell 2000 futures fell 0.3%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘neutral’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid low message volumes.Note that U.S. Treasury markets will close early at 2:00 PM ET today, while equity markets will trade for their regular session. However, markets will be closed on Thursday for New Year’s Day.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Nvidia (NVDA):&nbsp;Reports suggest that the company&nbsp;is scrambling to meet the demand for its H200 AI chips from Chinese companies and has asked its contract manufacturer, Taiwan Semiconductor Manufacturing Co., to ramp up output. It is also interesting to note that Wedbush’s Dan Ives laid out his top five AI picks for 2026 earlier this week, and Nvidia is not on that list.&nbsp; Vanda Pharma (VNDA):&nbsp;Has received FDA clearance for NEREUS (tradipitant), the first new motion sickness treatment in over 40 years. Tesla (TSLA): Stock is on retail radar after earlier weakness ahead of Q4 delivery takeaways due later this week. This comes even as the company officially signaled that Cybercab production has begun. Meanwhile, Michael Burry, the famed ‘Big Short’ investor, called Tesla’s market capitalization ‘ridiculously overvalued.’ With the Federal health subsidies under the Affordable Care Act expiring tonight (Dec 31), watch for healthcare provider and insurer stocks today. Other noteworthy tickers trending on Stocktwits at the time of writing were iShares Silver Trust (SLV), SPDR Gold Shares (GLD), Micron Technology (MU), and Viking Therapeutics (VKTX).Other Catalysts To Watch On the economic front, investors are looking ahead to the release of initial jobless claims, among other data releases. -Initial Jobless Claims (8:30 am ET) -Dec Chicago PMI (9:45 am ET) -EIA Crude Oil Inventories (10:30 am ET) For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower For Final Session Of 2025: Why NVDA, TSLA, VNDA Are On Traders' Radar Today

Investors head into the final trading session of 2025 with caution.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VNDA News

VNDAVanda Pharmaceuticals Inc